Skip to main content
Top
Published in: Endocrine Pathology 3/2008

01-09-2008

Controversies in Thyroid Pathology: The Diagnosis of Follicular Neoplasms

Authors: Stefano Serra, Sylvia L. Asa

Published in: Endocrine Pathology | Issue 3/2008

Login to get access

Abstract

Thyroid nodules are common; almost 20% of the population has a palpable thyroid nodule and approximately 70% has a nodule detected by ultrasound. Thyroid cancer is the most frequent endocrine malignancy, and incidence rates have steadily increased over the last decades. Papillary carcinoma (PTC) is the most common malignant neoplasm of the thyroid; the diagnosis of this most frequent type (85–90%) has been increasing, possibly due to changing recognition of morphologic criteria. PTC is defined histologically as a malignant tumor showing evidence of follicular epithelial differentiation and characterized by distinctive nuclear features. However, there are borderline lesions that do not completely fulfill these criteria, making the diagnosis difficult. The use of immunohistochemical and molecular markers adds objective criteria to this confusing and controversial area of pathology. We review the differential diagnosis of well-differentiated follicular thyroid neoplasms and the ancillary techniques and molecular characteristics that have been proposed for application in the diagnosis of PTC.
Literature
1.
go back to reference Ezzat S, Sarti DA, Cain DR, Braunstein GD. Thyroid incidentalomas. Prevalence by palpation and ultrasonography. Arch Intern Med 154(16):1838–40, 1994.PubMedCrossRef Ezzat S, Sarti DA, Cain DR, Braunstein GD. Thyroid incidentalomas. Prevalence by palpation and ultrasonography. Arch Intern Med 154(16):1838–40, 1994.PubMedCrossRef
2.
go back to reference Lloyd RV, Erickson LA, Casey MB, Lam KY, Lohse CM, Asa SL, et al. Observer variation in the diagnosis of follicular variant of papillary thyroid carcinoma. Am J Surg Pathol 28(10):1336–40, 2004.PubMedCrossRef Lloyd RV, Erickson LA, Casey MB, Lam KY, Lohse CM, Asa SL, et al. Observer variation in the diagnosis of follicular variant of papillary thyroid carcinoma. Am J Surg Pathol 28(10):1336–40, 2004.PubMedCrossRef
3.
go back to reference Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A, et al. Cancer statistics, 2005. CA Cancer J Clin 55(1):10–30, 2005.PubMedCrossRef Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A, et al. Cancer statistics, 2005. CA Cancer J Clin 55(1):10–30, 2005.PubMedCrossRef
4.
go back to reference DeLellis RALR, Heitz PU, Eng C. Pathology and genetics tumours of endocrine organs. WHO classification of tumours. Lyon, France: IARC, 2004. DeLellis RALR, Heitz PU, Eng C. Pathology and genetics tumours of endocrine organs. WHO classification of tumours. Lyon, France: IARC, 2004.
5.
go back to reference LiVolsi VA, Asa SL. The demise of follicular carcinoma of the thyroid gland. Thyroid 4(2):233–6, 1994.PubMed LiVolsi VA, Asa SL. The demise of follicular carcinoma of the thyroid gland. Thyroid 4(2):233–6, 1994.PubMed
6.
go back to reference Apel RL, Ezzat S, Bapat BV, Pan N, LiVolsi VA, Asa SL. Clonality of thyroid nodules in sporadic goiter. Diagn Mol Pathol 4(2):113–21, 1995.PubMedCrossRef Apel RL, Ezzat S, Bapat BV, Pan N, LiVolsi VA, Asa SL. Clonality of thyroid nodules in sporadic goiter. Diagn Mol Pathol 4(2):113–21, 1995.PubMedCrossRef
7.
go back to reference Aeschimann S, Kopp PA, Kimura ET, Zbaeren J, Tobler A, Fey MF, et al. Morphological and functional polymorphism within clonal thyroid nodules. J Clin Endocrinol Metab 77(3):846–51, 1993.PubMedCrossRef Aeschimann S, Kopp PA, Kimura ET, Zbaeren J, Tobler A, Fey MF, et al. Morphological and functional polymorphism within clonal thyroid nodules. J Clin Endocrinol Metab 77(3):846–51, 1993.PubMedCrossRef
8.
go back to reference Van Sande J, Parma J, Tonacchera M, Swillens S, Dumont J, Vassart G. Somatic and germline mutations of the TSH receptor gene in thyroid diseases. J Clin Endocrinol Metab 80(9):2577–85, 1995.PubMedCrossRef Van Sande J, Parma J, Tonacchera M, Swillens S, Dumont J, Vassart G. Somatic and germline mutations of the TSH receptor gene in thyroid diseases. J Clin Endocrinol Metab 80(9):2577–85, 1995.PubMedCrossRef
9.
go back to reference Lyons J, Landis CA, Harsh G, Vallar L, Grunewald K, Feichtinger H, et al. Two G protein oncogenes in human endocrine tumors. Science 249(4969):655–9, 1990.PubMedCrossRef Lyons J, Landis CA, Harsh G, Vallar L, Grunewald K, Feichtinger H, et al. Two G protein oncogenes in human endocrine tumors. Science 249(4969):655–9, 1990.PubMedCrossRef
10.
go back to reference Porcellini A, Ciullo I, Laviola L, Amabile G, Fenzi G, Avvedimento VE. Novel mutations of thyrotropin receptor gene in thyroid hyperfunctioning adenomas. Rapid identification by fine needle aspiration biopsy. J Clin Endocrinol Metab 79(2):657–61, 1994.PubMedCrossRef Porcellini A, Ciullo I, Laviola L, Amabile G, Fenzi G, Avvedimento VE. Novel mutations of thyrotropin receptor gene in thyroid hyperfunctioning adenomas. Rapid identification by fine needle aspiration biopsy. J Clin Endocrinol Metab 79(2):657–61, 1994.PubMedCrossRef
11.
go back to reference Parma J, Duprez L, Van Sande J, Hermans J, Rocmans P, Van Vliet G, et al. Diversity and prevalence of somatic mutations in the thyrotropin receptor and Gs alpha genes as a cause of toxic thyroid adenomas. J Clin Endocrinol Metab 82(8):2695–701, 1997.PubMedCrossRef Parma J, Duprez L, Van Sande J, Hermans J, Rocmans P, Van Vliet G, et al. Diversity and prevalence of somatic mutations in the thyrotropin receptor and Gs alpha genes as a cause of toxic thyroid adenomas. J Clin Endocrinol Metab 82(8):2695–701, 1997.PubMedCrossRef
12.
go back to reference Krohn K, Fuhrer D, Holzapfel HP, Paschke R. Clonal origin of toxic thyroid nodules with constitutively activating thyrotropin receptor mutations. J Clin Endocrinol Metab 83(1):130–4, 1998.PubMedCrossRef Krohn K, Fuhrer D, Holzapfel HP, Paschke R. Clonal origin of toxic thyroid nodules with constitutively activating thyrotropin receptor mutations. J Clin Endocrinol Metab 83(1):130–4, 1998.PubMedCrossRef
13.
go back to reference Kondo T, Ezzat S, Asa SL. Pathogenetic mechanisms in thyroid follicular-cell neoplasia. Nat Rev Cancer 6(4):292–306, 2006.PubMedCrossRef Kondo T, Ezzat S, Asa SL. Pathogenetic mechanisms in thyroid follicular-cell neoplasia. Nat Rev Cancer 6(4):292–306, 2006.PubMedCrossRef
14.
go back to reference Yamashina M. Follicular neoplasms of the thyroid. Total circumferential evaluation of the fibrous capsule. Am J Surg Pathol 16(4):392–400, 1992.PubMedCrossRef Yamashina M. Follicular neoplasms of the thyroid. Total circumferential evaluation of the fibrous capsule. Am J Surg Pathol 16(4):392–400, 1992.PubMedCrossRef
15.
go back to reference van Heerden JA, Hay ID, Goellner JR, Salomao D, Ebersold JR, Bergstralh EJ, et al. Follicular thyroid carcinoma with capsular invasion alone: a nonthreatening malignancy. Surgery 112(6):1130–6, 1992, discussion 1136–8.PubMed van Heerden JA, Hay ID, Goellner JR, Salomao D, Ebersold JR, Bergstralh EJ, et al. Follicular thyroid carcinoma with capsular invasion alone: a nonthreatening malignancy. Surgery 112(6):1130–6, 1992, discussion 1136–8.PubMed
16.
go back to reference Harness JK, Thompson NW, McLeod MK, Eckhauser FE, Lloyd RV. Follicular carcinoma of the thyroid gland: trends and treatment. Surgery 96(6):972–80, 1984.PubMed Harness JK, Thompson NW, McLeod MK, Eckhauser FE, Lloyd RV. Follicular carcinoma of the thyroid gland: trends and treatment. Surgery 96(6):972–80, 1984.PubMed
17.
go back to reference Lang BH, Lo CY, Chan WF, Lam AK, Wan KY. Classical and follicular variant of papillary thyroid carcinoma: a comparative study on clinicopathologic features and long-term outcome. World J Surg 30(5):752–8, 2006.PubMedCrossRef Lang BH, Lo CY, Chan WF, Lam AK, Wan KY. Classical and follicular variant of papillary thyroid carcinoma: a comparative study on clinicopathologic features and long-term outcome. World J Surg 30(5):752–8, 2006.PubMedCrossRef
18.
go back to reference Cheung CC, Ezzat S, Ramyar L, Freeman JL, Asa SL. Molecular basis off Hurthle cell papillary thyroid carcinoma. J Clin Endocrinol Metab 85(2):878–82, 2000.PubMedCrossRef Cheung CC, Ezzat S, Ramyar L, Freeman JL, Asa SL. Molecular basis off Hurthle cell papillary thyroid carcinoma. J Clin Endocrinol Metab 85(2):878–82, 2000.PubMedCrossRef
19.
20.
go back to reference Carcangiu ML, Sibley RK, Rosai J. Clear cell change in primary thyroid tumors. A study of 38 cases. Am J Surg Pathol 9(10):705–22, 1985.PubMedCrossRef Carcangiu ML, Sibley RK, Rosai J. Clear cell change in primary thyroid tumors. A study of 38 cases. Am J Surg Pathol 9(10):705–22, 1985.PubMedCrossRef
21.
go back to reference Schmid KW, Farid NR. How to define follicular thyroid carcinoma? Virchows Arch 448(4):385–93, 2006.PubMedCrossRef Schmid KW, Farid NR. How to define follicular thyroid carcinoma? Virchows Arch 448(4):385–93, 2006.PubMedCrossRef
22.
go back to reference Cheung CC, Ezzat S, Freeman JL, Rosen IB, Asa SL. Immunohistochemical diagnosis of papillary thyroid carcinoma. Mod Pathol 14(4):338–42, 2001.PubMedCrossRef Cheung CC, Ezzat S, Freeman JL, Rosen IB, Asa SL. Immunohistochemical diagnosis of papillary thyroid carcinoma. Mod Pathol 14(4):338–42, 2001.PubMedCrossRef
23.
go back to reference Ito Y, Yoshida H, Tomoda C, Miya A, Kobayashi K, Matsuzuka F, et al. HBME-1 expression in follicular tumor of the thyroid: an investigation of whether it can be used as a marker to diagnose follicular carcinoma. Anticancer Res 25(1A):179–82, 2005.PubMed Ito Y, Yoshida H, Tomoda C, Miya A, Kobayashi K, Matsuzuka F, et al. HBME-1 expression in follicular tumor of the thyroid: an investigation of whether it can be used as a marker to diagnose follicular carcinoma. Anticancer Res 25(1A):179–82, 2005.PubMed
24.
go back to reference Mase T, Funahashi H, Koshikawa T, Imai T, Nara Y, Tanaka Y, et al. HBME-1 immunostaining in thyroid tumors especially in follicular neoplasm. Endocr J 50(2):173–7, 2003.PubMedCrossRef Mase T, Funahashi H, Koshikawa T, Imai T, Nara Y, Tanaka Y, et al. HBME-1 immunostaining in thyroid tumors especially in follicular neoplasm. Endocr J 50(2):173–7, 2003.PubMedCrossRef
25.
go back to reference Papotti M, Rodriguez J, De Pompa R, Bartolazzi A, Rosai J. Galectin-3 and HBME-1 expression in well-differentiated thyroid tumors with follicular architecture of uncertain malignant potential. Mod Pathol 18(4):541–6, 2005.PubMedCrossRef Papotti M, Rodriguez J, De Pompa R, Bartolazzi A, Rosai J. Galectin-3 and HBME-1 expression in well-differentiated thyroid tumors with follicular architecture of uncertain malignant potential. Mod Pathol 18(4):541–6, 2005.PubMedCrossRef
26.
go back to reference de Matos PS, Ferreira AP, de Oliveira Facuri F, Assumpcao LV, Metze K, Ward LS. Usefulness of HBME-1, cytokeratin 19 and galectin-3 immunostaining in the diagnosis of thyroid malignancy. Histopathology 47(4):391–401, 2005.PubMedCrossRef de Matos PS, Ferreira AP, de Oliveira Facuri F, Assumpcao LV, Metze K, Ward LS. Usefulness of HBME-1, cytokeratin 19 and galectin-3 immunostaining in the diagnosis of thyroid malignancy. Histopathology 47(4):391–401, 2005.PubMedCrossRef
27.
go back to reference Prasad ML, Pellegata NS, Huang Y, Nagaraja HN, de la Chapelle A, Kloos RT. Galectin-3, fibronectin-1, CITED-1, HBME1 and cytokeratin-19 immunohistochemistry is useful for the differential diagnosis of thyroid tumors. Mod Pathol 18(1):48–57, 2005.PubMedCrossRef Prasad ML, Pellegata NS, Huang Y, Nagaraja HN, de la Chapelle A, Kloos RT. Galectin-3, fibronectin-1, CITED-1, HBME1 and cytokeratin-19 immunohistochemistry is useful for the differential diagnosis of thyroid tumors. Mod Pathol 18(1):48–57, 2005.PubMedCrossRef
28.
go back to reference Volante M, Bozzalla-Cassione F, DePompa R, Saggiorato E, Bartolazzi A, Orlandi F, et al. Galectin-3 and HBME-1 expression in oncocytic cell tumors of the thyroid. Virchows Arch 445(2):183–8, 2004.PubMedCrossRef Volante M, Bozzalla-Cassione F, DePompa R, Saggiorato E, Bartolazzi A, Orlandi F, et al. Galectin-3 and HBME-1 expression in oncocytic cell tumors of the thyroid. Virchows Arch 445(2):183–8, 2004.PubMedCrossRef
29.
go back to reference Mai KT, Bokhary R, Yazdi HM, Thomas J, Commons AS. Reduced HBME-1 immunoreactivity of papillary thyroid carcinoma and papillary thyroid carcinoma-related neoplastic lesions with Hurthle cell and/or apocrine-like changes. Histopathology 40(2):133–42, 2002.PubMedCrossRef Mai KT, Bokhary R, Yazdi HM, Thomas J, Commons AS. Reduced HBME-1 immunoreactivity of papillary thyroid carcinoma and papillary thyroid carcinoma-related neoplastic lesions with Hurthle cell and/or apocrine-like changes. Histopathology 40(2):133–42, 2002.PubMedCrossRef
30.
go back to reference Bartolazzi A, Bussolati G. Galectin-3 does not reliably distinguish benign from malignant thyroid neoplasms. Histopathology 48(2):212–3, 2006.PubMedCrossRef Bartolazzi A, Bussolati G. Galectin-3 does not reliably distinguish benign from malignant thyroid neoplasms. Histopathology 48(2):212–3, 2006.PubMedCrossRef
31.
go back to reference Mehrotra P, Okpokam A, Bouhaidar R, Johnson SJ, Wilson JA, Davies BR, et al. Galectin-3 does not reliably distinguish benign from malignant thyroid neoplasms. Histopathology 45(5):493–500, 2004.PubMedCrossRef Mehrotra P, Okpokam A, Bouhaidar R, Johnson SJ, Wilson JA, Davies BR, et al. Galectin-3 does not reliably distinguish benign from malignant thyroid neoplasms. Histopathology 45(5):493–500, 2004.PubMedCrossRef
32.
go back to reference Mills LJ, Poller DN, Yiangou C. Galectin-3 is not useful in thyroid FNA. Cytopathology 16(3):132–8, 2005.PubMedCrossRef Mills LJ, Poller DN, Yiangou C. Galectin-3 is not useful in thyroid FNA. Cytopathology 16(3):132–8, 2005.PubMedCrossRef
33.
go back to reference Cvejic D, Savin S, Petrovic I, Paunovic I, Tatic S, Krgovic K, et al. Galectin-3 expression in papillary microcarcinoma of the thyroid. Histopathology 47(2):209–14, 2005.PubMedCrossRef Cvejic D, Savin S, Petrovic I, Paunovic I, Tatic S, Krgovic K, et al. Galectin-3 expression in papillary microcarcinoma of the thyroid. Histopathology 47(2):209–14, 2005.PubMedCrossRef
34.
go back to reference Weber KB, Shroyer KR, Heinz DE, Nawaz S, Said MS, Haugen BR. The use of a combination of galectin-3 and thyroid peroxidase for the diagnosis and prognosis of thyroid cancer. Am J Clin Pathol 122(4):524–31, 2004.PubMedCrossRef Weber KB, Shroyer KR, Heinz DE, Nawaz S, Said MS, Haugen BR. The use of a combination of galectin-3 and thyroid peroxidase for the diagnosis and prognosis of thyroid cancer. Am J Clin Pathol 122(4):524–31, 2004.PubMedCrossRef
35.
go back to reference Cvejic DS, Savin SB, Petrovic IM, Paunovic IR, Tatic SB, Havelka MJ. Galectin-3 expression in papillary thyroid carcinoma: relation to histomorphologic growth pattern, lymph node metastasis, extrathyroid invasion, and tumor size. Head Neck 27(12):1049–55, 2005.PubMedCrossRef Cvejic DS, Savin SB, Petrovic IM, Paunovic IR, Tatic SB, Havelka MJ. Galectin-3 expression in papillary thyroid carcinoma: relation to histomorphologic growth pattern, lymph node metastasis, extrathyroid invasion, and tumor size. Head Neck 27(12):1049–55, 2005.PubMedCrossRef
36.
go back to reference Oestreicher-Kedem Y, Halpern M, Roizman P, Hardy B, Sulkes J, Feinmesser R, et al. Diagnostic value of galectin-3 as a marker for malignancy in follicular patterned thyroid lesions. Head Neck 26(11):960–6, 2004.PubMedCrossRef Oestreicher-Kedem Y, Halpern M, Roizman P, Hardy B, Sulkes J, Feinmesser R, et al. Diagnostic value of galectin-3 as a marker for malignancy in follicular patterned thyroid lesions. Head Neck 26(11):960–6, 2004.PubMedCrossRef
37.
go back to reference Gasbarri A, Sciacchitano S, Marasco A, Papotti M, Di Napoli A, Marzullo A, et al. Detection and molecular characterisation of thyroid cancer precursor lesions in a specific subset of Hashimoto’s thyroiditis. Br J Cancer 91(6):1096–104, 2004.PubMed Gasbarri A, Sciacchitano S, Marasco A, Papotti M, Di Napoli A, Marzullo A, et al. Detection and molecular characterisation of thyroid cancer precursor lesions in a specific subset of Hashimoto’s thyroiditis. Br J Cancer 91(6):1096–104, 2004.PubMed
38.
go back to reference Sahoo S, Hoda SA, Rosai J, DeLellis RA. Cytokeratin 19 immunoreactivity in the diagnosis of papillary thyroid carcinoma: a note of caution. Am J Clin Pathol 116(5):696–702, 2001.PubMedCrossRef Sahoo S, Hoda SA, Rosai J, DeLellis RA. Cytokeratin 19 immunoreactivity in the diagnosis of papillary thyroid carcinoma: a note of caution. Am J Clin Pathol 116(5):696–702, 2001.PubMedCrossRef
39.
go back to reference Fusco A, Chiappetta G, Hui P, Garcia-Rostan G, Golden L, Kinder BK, et al. Assessment of RET/PTC oncogene activation and clonality in thyroid nodules with incomplete morphological evidence of papillary carcinoma: a search for the early precursors of papillary cancer. Am J Pathol 160(6):2157–67, 2002.PubMed Fusco A, Chiappetta G, Hui P, Garcia-Rostan G, Golden L, Kinder BK, et al. Assessment of RET/PTC oncogene activation and clonality in thyroid nodules with incomplete morphological evidence of papillary carcinoma: a search for the early precursors of papillary cancer. Am J Pathol 160(6):2157–67, 2002.PubMed
40.
go back to reference Adeniran AJ, Zhu Z, Gandhi M, Steward DL, Fidler JP, Giordano TJ, et al. Correlation between genetic alterations and microscopic features, clinical manifestations, and prognostic characteristics of thyroid papillary carcinomas. Am J Surg Pathol 30(2):216–22, 2006.PubMedCrossRef Adeniran AJ, Zhu Z, Gandhi M, Steward DL, Fidler JP, Giordano TJ, et al. Correlation between genetic alterations and microscopic features, clinical manifestations, and prognostic characteristics of thyroid papillary carcinomas. Am J Surg Pathol 30(2):216–22, 2006.PubMedCrossRef
41.
go back to reference Liu W, Asa SL, Ezzat S. 1alpha,25-Dihydroxyvitamin D3 targets PTEN-dependent fibronectin expression to restore thyroid cancer cell adhesiveness. Mol Endocrinol 19(9):2349–57, 2005.PubMedCrossRef Liu W, Asa SL, Ezzat S. 1alpha,25-Dihydroxyvitamin D3 targets PTEN-dependent fibronectin expression to restore thyroid cancer cell adhesiveness. Mol Endocrinol 19(9):2349–57, 2005.PubMedCrossRef
42.
go back to reference Liu W, Wei W, Winer D, Bamberger AM, Bamberger C, Wagener C, et al. CEACAM1 impedes thyroid cancer growth but promotes invasiveness: a putative mechanism for early metastases. Oncogene 26(19):2747–58, 2007.PubMedCrossRef Liu W, Wei W, Winer D, Bamberger AM, Bamberger C, Wagener C, et al. CEACAM1 impedes thyroid cancer growth but promotes invasiveness: a putative mechanism for early metastases. Oncogene 26(19):2747–58, 2007.PubMedCrossRef
43.
go back to reference Rossi ED, Raffaelli M, Mule A, Miraglia A, Lombardi CP, Vecchio FM, et al. Simultaneous immunohistochemical expression of HBME-1 and galectin-3 differentiates papillary carcinomas from hyperfunctioning lesions of the thyroid. Histopathology 48(7):795–800, 2006.PubMedCrossRef Rossi ED, Raffaelli M, Mule A, Miraglia A, Lombardi CP, Vecchio FM, et al. Simultaneous immunohistochemical expression of HBME-1 and galectin-3 differentiates papillary carcinomas from hyperfunctioning lesions of the thyroid. Histopathology 48(7):795–800, 2006.PubMedCrossRef
44.
go back to reference Savin S, Cvejic D, Isic T, Petrovic I, Paunovic I, Tatic S, et al. Thyroid peroxidase immunohistochemistry in differential diagnosis of thyroid tumors. Endocr Pathol 17(1):53–60, 2006.PubMedCrossRef Savin S, Cvejic D, Isic T, Petrovic I, Paunovic I, Tatic S, et al. Thyroid peroxidase immunohistochemistry in differential diagnosis of thyroid tumors. Endocr Pathol 17(1):53–60, 2006.PubMedCrossRef
45.
go back to reference Finley DJ, Arora N, Zhu B, Gallagher L, Fahey TJ 3rd. Molecular profiling distinguishes papillary carcinoma from benign thyroid nodules. J Clin Endocrinol Metab 89(7):3214–23, 2004.PubMedCrossRef Finley DJ, Arora N, Zhu B, Gallagher L, Fahey TJ 3rd. Molecular profiling distinguishes papillary carcinoma from benign thyroid nodules. J Clin Endocrinol Metab 89(7):3214–23, 2004.PubMedCrossRef
46.
go back to reference Rebelo S, Domingues R, Catarino AL, Mendonca E, Santos JR, Sobrinho L, et al. Immunostaining and RT-PCR: different approaches to search for RET rearrangements in patients with papillary thyroid carcinoma. Int J Oncol 23(4):1025–32, 2003.PubMed Rebelo S, Domingues R, Catarino AL, Mendonca E, Santos JR, Sobrinho L, et al. Immunostaining and RT-PCR: different approaches to search for RET rearrangements in patients with papillary thyroid carcinoma. Int J Oncol 23(4):1025–32, 2003.PubMed
47.
go back to reference Rhoden KJ, Unger K, Salvatore G, Yilmaz Y, Vovk V, Chiappetta G, et al. RET/papillary thyroid cancer rearrangement in nonneoplastic thyrocytes: follicular cells of Hashimoto’s thyroiditis share low-level recombination events with a subset of papillary carcinoma. J Clin Endocrinol Metab 91(6):2414–23, 2006.PubMedCrossRef Rhoden KJ, Unger K, Salvatore G, Yilmaz Y, Vovk V, Chiappetta G, et al. RET/papillary thyroid cancer rearrangement in nonneoplastic thyrocytes: follicular cells of Hashimoto’s thyroiditis share low-level recombination events with a subset of papillary carcinoma. J Clin Endocrinol Metab 91(6):2414–23, 2006.PubMedCrossRef
48.
go back to reference Nikiforov YE, Rowland JM, Bove KE, Monforte-Munoz H, Fagin JA. Distinct pattern of ret oncogene rearrangements in morphological variants of radiation-induced and sporadic thyroid papillary carcinomas in children. Cancer Res 57(9):1690–4, 1997.PubMed Nikiforov YE, Rowland JM, Bove KE, Monforte-Munoz H, Fagin JA. Distinct pattern of ret oncogene rearrangements in morphological variants of radiation-induced and sporadic thyroid papillary carcinomas in children. Cancer Res 57(9):1690–4, 1997.PubMed
49.
go back to reference Chiappetta G, Toti P, Cetta F, Giuliano A, Pentimalli F, Amendola I, et al. The RET/PTC oncogene is frequently activated in oncocytic thyroid tumors (Hurthle cell adenomas and carcinomas), but not in oncocytic hyperplastic lesions. J Clin Endocrinol Metab 87(1):364–9, 2002.PubMedCrossRef Chiappetta G, Toti P, Cetta F, Giuliano A, Pentimalli F, Amendola I, et al. The RET/PTC oncogene is frequently activated in oncocytic thyroid tumors (Hurthle cell adenomas and carcinomas), but not in oncocytic hyperplastic lesions. J Clin Endocrinol Metab 87(1):364–9, 2002.PubMedCrossRef
50.
go back to reference Maxwell EL, Palme CE, Freeman J. Hurthle cell tumors: applying molecular markers to define a new management algorithm. Arch Otolaryngol Head Neck Surg 132(1):54–8, 2006.PubMedCrossRef Maxwell EL, Palme CE, Freeman J. Hurthle cell tumors: applying molecular markers to define a new management algorithm. Arch Otolaryngol Head Neck Surg 132(1):54–8, 2006.PubMedCrossRef
51.
go back to reference Dailey ME, Lindsay S, Skahen R. Relation of thyroid neoplasms to Hashimoto disease of the thyroid gland. AMA Arch Surg 70(2):291–7, 1955.PubMed Dailey ME, Lindsay S, Skahen R. Relation of thyroid neoplasms to Hashimoto disease of the thyroid gland. AMA Arch Surg 70(2):291–7, 1955.PubMed
52.
go back to reference Larson SD, Jackson LN, Riall TS, Uchida T, Thomas RP, Qiu S, et al. Increased incidence of well-differentiated thyroid cancer associated with Hashimoto thyroiditis and the role of the PI3k/Akt pathway. J Am Coll Surg 204(5):764–73, 2007, discussion 773–5.PubMedCrossRef Larson SD, Jackson LN, Riall TS, Uchida T, Thomas RP, Qiu S, et al. Increased incidence of well-differentiated thyroid cancer associated with Hashimoto thyroiditis and the role of the PI3k/Akt pathway. J Am Coll Surg 204(5):764–73, 2007, discussion 773–5.PubMedCrossRef
54.
go back to reference Ugolini C, Giannini R, Lupi C, Salvatore G, Miccoli P, Proietti A, et al. Presence of BRAF V600E in very early stages of papillary thyroid carcinoma. Thyroid 17(5):381–8, 2007.PubMedCrossRef Ugolini C, Giannini R, Lupi C, Salvatore G, Miccoli P, Proietti A, et al. Presence of BRAF V600E in very early stages of papillary thyroid carcinoma. Thyroid 17(5):381–8, 2007.PubMedCrossRef
55.
go back to reference Costa AM, Herrero A, Fresno MF, Heymann J, Alvarez JA, Cameselle-Teijeiro J, et al. BRAF mutation associated with other genetic events identifies a subset of aggressive papillary thyroid carcinoma. Clin Endocrinol (Oxf) 68(4):618–34, 2008.CrossRef Costa AM, Herrero A, Fresno MF, Heymann J, Alvarez JA, Cameselle-Teijeiro J, et al. BRAF mutation associated with other genetic events identifies a subset of aggressive papillary thyroid carcinoma. Clin Endocrinol (Oxf) 68(4):618–34, 2008.CrossRef
56.
go back to reference Zhu Z, Gandhi M, Nikiforova MN, Fischer AH, Nikiforov YE. Molecular profile and clinical-pathologic features of the follicular variant of papillary thyroid carcinoma. An unusually high prevalence of ras mutations. Am J Clin Pathol 120(1):71–7, 2003.PubMedCrossRef Zhu Z, Gandhi M, Nikiforova MN, Fischer AH, Nikiforov YE. Molecular profile and clinical-pathologic features of the follicular variant of papillary thyroid carcinoma. An unusually high prevalence of ras mutations. Am J Clin Pathol 120(1):71–7, 2003.PubMedCrossRef
57.
go back to reference Kroll TG, Sarraf P, Pecciarini L, Chen CJ, Mueller E, Spiegelman BM, et al. PAX8-PPARgamma1 fusion oncogene in human thyroid carcinoma [corrected]. Science 289(5483):1357–60, 2000.PubMedCrossRef Kroll TG, Sarraf P, Pecciarini L, Chen CJ, Mueller E, Spiegelman BM, et al. PAX8-PPARgamma1 fusion oncogene in human thyroid carcinoma [corrected]. Science 289(5483):1357–60, 2000.PubMedCrossRef
58.
go back to reference Castro P, Rebocho AP, Soares RJ, Magalhaes J, Roque L, Trovisco V, et al. PAX8-PPARgamma rearrangement is frequently detected in the follicular variant of papillary thyroid carcinoma. J Clin Endocrinol Metab 91(1):213–20, 2006.PubMedCrossRef Castro P, Rebocho AP, Soares RJ, Magalhaes J, Roque L, Trovisco V, et al. PAX8-PPARgamma rearrangement is frequently detected in the follicular variant of papillary thyroid carcinoma. J Clin Endocrinol Metab 91(1):213–20, 2006.PubMedCrossRef
59.
go back to reference Nakamura T, Yana I, Kobayashi T, Shin E, Karakawa K, Fujita S, et al. p53 gene mutations associated with anaplastic transformation of human thyroid carcinomas. Jpn J Cancer Res 83(12):1293–8, 1992.PubMed Nakamura T, Yana I, Kobayashi T, Shin E, Karakawa K, Fujita S, et al. p53 gene mutations associated with anaplastic transformation of human thyroid carcinomas. Jpn J Cancer Res 83(12):1293–8, 1992.PubMed
60.
go back to reference Hunt JL, Tometsko M, LiVolsi VA, Swalsky P, Finkelstein SD, Barnes EL. Molecular evidence of anaplastic transformation in coexisting well-differentiated and anaplastic carcinomas of the thyroid. Am J Surg Pathol 27(12):1559–64, 2003.PubMedCrossRef Hunt JL, Tometsko M, LiVolsi VA, Swalsky P, Finkelstein SD, Barnes EL. Molecular evidence of anaplastic transformation in coexisting well-differentiated and anaplastic carcinomas of the thyroid. Am J Surg Pathol 27(12):1559–64, 2003.PubMedCrossRef
Metadata
Title
Controversies in Thyroid Pathology: The Diagnosis of Follicular Neoplasms
Authors
Stefano Serra
Sylvia L. Asa
Publication date
01-09-2008
Publisher
Humana Press Inc
Published in
Endocrine Pathology / Issue 3/2008
Print ISSN: 1046-3976
Electronic ISSN: 1559-0097
DOI
https://doi.org/10.1007/s12022-008-9031-5

Other articles of this Issue 3/2008

Endocrine Pathology 3/2008 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.